KMT2A and Bjornstad syndrome: Various KMT2A-associated malignancies, especially KMT2A-PTD and KMT2A-a leukemias, which exhibit unfavorable prognoses and require improved therapeutic options, may benefit from WT KMT2A inhibitors.